Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Medica
Cervical Cancer
Initial criteria
- age ≥ 18 years
- persistent, recurrent, or metastatic disease
- used in combination with chemotherapy (e.g., cisplatin or carboplatin with etoposide)
- prescribed by or in consultation with an oncologist
Approval duration
1 year